Ahmed Khattab1, Sunita Patruni1, Stephen Abel2, Shaakir Hasan2, Ethan B Ludmir3, Gene Finley4, Dulabh Monga4, Rodney E Wegner2, Vivek Verma2. 1. Allegheny Health Network, Department of Internal Medicine, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. 2. Division of Radiation Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. 3. Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 4. Division of Medical Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA.
Abstract
BACKGROUND: Response of pancreatic adenocarcinoma to neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) may be associated with prognosis, but long-term outcomes based on response to neoadjuvant therapy have not been well evaluated to date. METHODS: The National Cancer Database was queried for patients with pancreatic adenocarcinoma receiving nCT/nCRT. To evaluate response to nCT/nCRT, comparisons were made from cT and cN stage to the respective post-neoadjuvant therapy ypT and ypN stages. Based on these comparisons, patients were classified as responders, progressors, or non-responders. Statistical analyses included estimation of survival using Kaplan-Meier analysis, as well as multivariable Cox proportional hazards modeling. RESULTS: Of 2,028 patients, 30% had a response, 32% progressed, and 38% had no response; 1% of patients experienced pathologic complete response (pCR). Responders were more likely to have received multi-agent chemotherapy (P=0.0001) as well as radiotherapy (RT) (P=0.02) in the neoadjuvant setting. Response to nCT/nCRT was also associated with a higher R0 resection rate (P=0.02). At a median follow-up of 49 months, median overall survival (OS) was higher in responders than non-responders or progressors (29.9 vs. 24.3 vs. 22.2 months, P<0.001). The mean OS for patients experiencing pCR was 55.5 months. On multivariable analysis, treatment response was independently associated with OS (P=0.02). CONCLUSIONS: Response to nCT/nCRT independently predicts long-term outcomes following resection of pancreatic adenocarcinoma; higher rates of treatment response were observed for patients receiving neoadjuvant RT as well as neoadjuvant multi-agent chemotherapy. These results may have implications on strategies to improve response rates. 2019 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: Response of pancreatic adenocarcinoma to neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) may be associated with prognosis, but long-term outcomes based on response to neoadjuvant therapy have not been well evaluated to date. METHODS: The National Cancer Database was queried for patients with pancreatic adenocarcinoma receiving nCT/nCRT. To evaluate response to nCT/nCRT, comparisons were made from cT and cN stage to the respective post-neoadjuvant therapy ypT and ypN stages. Based on these comparisons, patients were classified as responders, progressors, or non-responders. Statistical analyses included estimation of survival using Kaplan-Meier analysis, as well as multivariable Cox proportional hazards modeling. RESULTS: Of 2,028 patients, 30% had a response, 32% progressed, and 38% had no response; 1% of patients experienced pathologic complete response (pCR). Responders were more likely to have received multi-agent chemotherapy (P=0.0001) as well as radiotherapy (RT) (P=0.02) in the neoadjuvant setting. Response to nCT/nCRT was also associated with a higher R0 resection rate (P=0.02). At a median follow-up of 49 months, median overall survival (OS) was higher in responders than non-responders or progressors (29.9 vs. 24.3 vs. 22.2 months, P<0.001). The mean OS for patients experiencing pCR was 55.5 months. On multivariable analysis, treatment response was independently associated with OS (P=0.02). CONCLUSIONS: Response to nCT/nCRT independently predicts long-term outcomes following resection of pancreatic adenocarcinoma; higher rates of treatment response were observed for patients receiving neoadjuvant RT as well as neoadjuvant multi-agent chemotherapy. These results may have implications on strategies to improve response rates. 2019 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Peter J Allen; Deborah Kuk; Carlos Fernandez-Del Castillo; Olca Basturk; Christopher L Wolfgang; John L Cameron; Keith D Lillemoe; Cristina R Ferrone; Vicente Morales-Oyarvide; Jin He; Matthew J Weiss; Ralph H Hruban; Mithat Gönen; David S Klimstra; Mari Mino-Kenudson Journal: Ann Surg Date: 2017-01 Impact factor: 12.969
Authors: J P Neoptolemos; D D Stocken; J A Dunn; J Almond; H G Beger; P Pederzoli; C Bassi; C Dervenis; L Fernandez-Cruz; F Lacaine; J Buckels; M Deakin; F A Adab; R Sutton; C Imrie; I Ihse; T Tihanyi; A Olah; S Pedrazzoli; D Spooner; D J Kerr; H Friess; M W Büchler Journal: Ann Surg Date: 2001-12 Impact factor: 12.969
Authors: John P Neoptolemos; Deborah D Stocken; Claudio Bassi; Paula Ghaneh; David Cunningham; David Goldstein; Robert Padbury; Malcolm J Moore; Steven Gallinger; Christophe Mariette; Moritz N Wente; Jakob R Izbicki; Helmut Friess; Markus M Lerch; Christos Dervenis; Attila Oláh; Giovanni Butturini; Ryuichiro Doi; Pehr A Lind; David Smith; Juan W Valle; Daniel H Palmer; John A Buckels; Joyce Thompson; Colin J McKay; Charlotte L Rawcliffe; Markus W Büchler Journal: JAMA Date: 2010-09-08 Impact factor: 56.272
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti Journal: Ann Surg Date: 2007-08 Impact factor: 12.969
Authors: Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: Dany Barrak; Anthony M Villano; Nicole Villafane-Ferriol; Leah G Stockton; Maureen V Hill; Mengying Deng; Elizabeth A Handorf; Sanjay S Reddy Journal: Eur J Surg Oncol Date: 2022-01-05 Impact factor: 4.037
Authors: Asmita Chopra; Jacob C Hodges; Adam Olson; Steve Burton; Susannah G Ellsworth; Nathan Bahary; Aatur D Singhi; Brian A Boone; Joal D Beane; David Bartlett; Kenneth K Lee; Melissa E Hogg; Michael T Lotze; Alessandro Paniccia; Herbert Zeh; Amer H Zureikat Journal: Ann Surg Oncol Date: 2020-11-24 Impact factor: 4.339
Authors: R Casolino; C Braconi; G Malleo; S Paiella; C Bassi; M Milella; S B Dreyer; F E M Froeling; D K Chang; A V Biankin; T Golan Journal: Ann Oncol Date: 2020-11-26 Impact factor: 32.976